Canaccord analyst Elyse Shapiro downgraded Mayne Pharma to Hold from Buy with a price target of A$3.80, down from A$7.40. The analyst sees a lot for new management to work through after the company divested its retail generics portfolio.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MAYNF: